Sample Logistics and Screening Evaluation

- After execution of a Material Transfer Agreement (MTA), AstraZeneca supplies the external investigator with bar-coded vessels for transfer of solid or liquid samples, shipping instructions, and the format for data transfer.
- Upon receipt, solid compounds are solubilised in DMSO for entry into the screening programme.
- DMSO solutions must be at least 80% pure based on contemporary analytical characterisation and may be subject to purity analysis prior to entering the screening evaluation.
- After one year, a detailed HTS screening report is released to the external investigator. The investigator can then opt to continue screening compounds or request a withdrawal from the programme.
- The HTS screening report includes primary and secondary screening data as well as target type and assay format information.
- 10% of compounds selected for screening will also be tested in the panel of toxicity, DMPK and physical chemistry assays:
    - hERG
    - THP-1 (general cytotoxicity)
    - Mitochondrial toxicity
    - Aryl hydrocarbon receptor
    - Phospholipidosis
    - Log D
    - DMSO solubility
    - Human microsome metabolism
    - Rat hepatocyte metabolism
    - Human plasma protein binding
- A report summarising the data generated from the assay panel will be shared with external investigators within weeks of compounds being transferred to AstraZeneca.

Further Research (Partnership) Activities

- If a compound exhibits promising biological activity, AstraZeneca and the external investigator can negotiate further research activities by mutual consent.
- As all intellectual property rights will remain with the external investigator throughout, discussions will focus on how both parties can best advance the research through collaboration or licensing.
- Further biological characterisation will only proceed after a collaboration or licensing agreement has been established.
- The external investigator is free to publish the data, use in a grant application, and/or refine a hypothesis if mutual consent is not reached or the compound does not show promising biological activity.